Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma. [EARLY_Phase 1]
An early-phase 1 clinical trial to assess the safety and preliminary efficacy of QI-019A in relapsed/refractory multiple myeloma; the study …
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma [Phase 2]
The Phase 2 MagnetisMM-4 umbrella study evaluating elranatamab in combination with anti-cancer therapies for multiple myeloma was terminated…
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating adverse events and changes in disease activity of oral ABBV-453, given alone or with subcutaneous and/…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 clinical trial update evaluating anti-BCMA CAR-T cells for relapsed or refractory multiple myeloma; the study is currently active bu…
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma [Phase 3]
A Phase 3 trial evaluating induction therapy with lenalidomide, bortezomib, and dexamethasone plus isatuximab given either intravenously or …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency [Phase 2]
A Phase 2 clinical trial evaluating denosumab in patients with multiple myeloma and renal insufficiency has been completed.
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
A Phase 1 study evaluating the safety, effectiveness and tolerable dose of Arlocabtagene Autoleucel (BMS-986393) in novel combination regime…
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: CAR-T Immunomonitoring in Multiple Myeloma (CART I5M) [NA]
This clinical trial entry CART I5M is evaluating CAR-T immunomonitoring in multiple myeloma and is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation [Phase 2]
Phase 2 trial of daratumumab with lenalidomide, bortezomib, and dexamethasone induction (Dara-RVd) for newly diagnosed multiple myeloma unde…
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
Expanded Access Program update for cilta-cel in multiple myeloma noting out-of-specification results observed in participants.
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating GPC 100 and Propranolol, with and without G-CSF, for mobilizing stem cells in multiple myeloma patients undergoing …
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma [Phase 1]
A Phase 1 study evaluating BCMA-directed CAR-T cell therapy for relapsed/refractory multiple myeloma has completed enrollment, as reported b…
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant [Phase 2]
Phase 2 study of Daratumumab (Darzalex) in relapsed multiple myeloma after stem cell transplant was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma [Phase 1]
Phase 1 trial evaluating adding KRT-232 (AMG 232) to standard chemotherapy in relapsed multiple myeloma, with plasmacytoma also listed; the …
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma [Phase 2]
Phase 2 study evaluating selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma; the tria…
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial update for Arlocabtagene autoleucel (BMS-986393), a GPRC5D-directed CAR T cell therapy, evaluating its use in adult…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
Phase 1 clinical trial evaluating CC-95266 in relapsed and/or refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) [Phase 1, Phase 2]
A Phase 1/2 safety, PK and efficacy study of CC-92480 as monotherapy and in combination with dexamethasone in relapsed and refractory multip…
-
CLINICAL_TRIALS trial_result · 2026-02-05Clinical Trial Update: Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) [Phase 1]
This document provides an update on a Phase 1 dose-escalation trial of cevostamab in participants with relapsed or refractory multiple myelo…
-
CLINICAL_TRIALS trial_result · 2026-02-05Clinical Trial Update: Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) [Phase 2]
Phase 2 trial of pomalidomide in combination with dexamethasone in multiple myeloma patients with Del(17p) or t(4;14) abnormalities; the stu…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma [Phase 3]
A Phase 3 clinical trial comparing iberdomide alone versus iberdomide plus isatuximab as maintenance therapy after autologous stem cell tran…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Phase I Trial of VS-6766 Alone and in Combination With Everolimus [Phase 1]
Completed Phase I trial evaluating VS-6766 alone and in combination with everolimus in patients with solid tumors, multiple myeloma, lung ca…
-
CLINICAL_TRIALS trial_result · 2026-01-27Clinical Trial Update: Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation [Phase 2]
A Phase 2 trial evaluating propylene glycol-free melphalan HCl (EVOMELA) with fludarabine and total body irradiation-based reduced-intensity…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders [EARLY_Phase 1]
An early-phase Phase 1 trial evaluating a GPRC5D-targeted CAR-T cell therapy for relapsed/refractory plasma cell disorders, with the study n…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant [Phase 2]
A Phase 2 trial evaluating lenalidomide with or without ixazomib and dexamethasone in patients with residual multiple myeloma after donor st…